GE11
GE11 EGFR-targeting peptide (YHWYGYTPQNVI)
12 Amino Acids · MW: ≈1435 g/mol
Amino Acids
12
Molecular Weight
≈1435 g/mol
Half-life
minutes to hours
Research Score
4.3
Studies
84
Storage
Store lyophilized at -20°C, reconstituted at 2-8°C
What is GE11?
A 12-amino-acid peptide that binds EGFR with high selectivity and is commonly used to target epithelial tumors. It is a popular ligand for EGFR-directed peptide-drug conjugates, liposomes, and polymer-drug systems.
Key Benefits & Mechanisms
EGFR targeting
small conjugation handle
epithelial tumor selectivity
Research Summary
GE11 has been used to direct payloads to EGFR-positive cells in breast, lung, and other tumor models, supporting its role as a compact targeting ligand for PDC design.
Related Peptides
GV1001
Human telomerase reverse transcriptase (hTERT) 611-626 peptide GV1001
A telomerase-derived 16-mer peptide developed as a cancer vaccine antigen. It is designed to trigger T-cell responses against hTERT-expressing tumors.
Cancer ResearchNelipepimut-S
HER2/neu-derived peptide vaccine Nelipepimut-S (E75; KIFGSLAFL)
A 9-mer HLA-A2/A3-restricted peptide from HER2/neu used as a vaccine antigen. It aims to expand cytotoxic T-cell responses against HER2-positive tumors.
Cancer ResearchWT1 peptide
Wilms tumor 1 (WT1) antigen-derived peptide RMFPNAPYL
A WT1-derived 9-mer peptide used in peptide-vaccine strategies for leukemias and solid tumors. It is intended to generate HLA-restricted cytotoxic T-cell responses against WT1-positive cancer cells.
Cancer ResearchSurvivin 2B peptide
Survivin 2B peptide (LMLGEFLKL)
A survivin-derived HLA-A24-restricted epitope investigated as a peptide vaccine antigen. It targets survivin, a frequently overexpressed inhibitor of apoptosis in tumors.
Cancer Research